📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 18:37
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
27 announcements match the current filters (relevance ≥ 5).
26% Revenue Growth in Q1 FY27; Record 16 New Surgical Facilities Launched
Dr. Agarwal's Health Care reported a strong Q1 FY27 with revenue from operations growing 26% YoY to ₹614 crore. The company achieved its highest-ever quarterly expansion by launching 16 new surgical facilities, bringing the total network to 285 centers. EBITDA margins remained robust at 28.5%, while PAT margins expanded by 127 bps to 8.9% despite losses from 23 new greenfield facilities launched in the last six months. Mature facilities (pre-FY23) demonstrated high operational efficiency with 16.3% same-store sales growth (SSSG).
Confidence: HIGH
What changedThe company has significantly accelerated its greenfield expansion pace, moving from 10 additions in FY23 to 16 in a single quarter, while maintaining double-digit SSSG in mature markets.
Why it mattersThe aggressive expansion (43% footprint increase in 18 months) combined with a shift toward high-value surgeries (Femto Cataract up 33.4%) indicates a strategy to capture market share in the organized eye care segment while improving revenue per surgery.
Q1 FY27 Revenue: ₹614 crRevenue Growth (YoY): 26%New Facilities (Q1): 16SSSG (Mature Centers): 16.3%EBITDA Margin: 28.5%Total Network Size: 285 facilities
📅 Short termThe stock may react positively to the record expansion pace and strong top-line growth, though greenfield losses from new centers could temper immediate bottom-line gains.
📈 Long termStructural growth is supported by the shift to organized healthcare and expansion into North India, which now comprises 31% of the network.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in ramping up 78 newly added centers
- Shortage of skilled ophthalmologists limiting surgical capacity
- Greenfield losses impacting group profitability in the short term
Key Highlights
Revenue from operations increased 26% YoY to ₹614 crore, representing 29.5% of TTM revenue in a single quarter.
Launched 16 new surgical facilities in Q1 FY27, the highest ever in a single quarter for the company.
Mature facilities (pre-FY23) recorded 16.3% YoY same-store sales growth, contributing 75.9% of group revenue.
High-end cataract surgeries accounted for 29.3% of the 67,000 total cataract procedures performed.
EBITDA grew 25.2% YoY to ₹177 crore, maintaining a strong margin of 28.5%.
👀 What to Watch
Investors should monitor the execution and break-even timeline of the 78 new centers added since March 2024. The completion of the pending merger, expected by mid-November 2026, is the next major corporate milestone to track.
44.6% PAT Growth in Q1 FY27; Dr. Agarwal's Expands to 304 Facilities
Dr. Agarwal's Health Care reported a robust Q1 FY27 with revenue growing 26% YoY to ₹614 Cr, supported by aggressive network expansion. Profit After Tax (PAT) surged 44.6% YoY to ₹55 Cr, while EBITDA margins remained healthy at 28.5%. The company added 18 new facilities during the quarter, bringing its total network to 304 centers across India and Africa. High-value surgical procedures like Femto Cataracts and Retinal surgeries saw volume growth of 33.4% and 30.0% respectively, driving the core surgical revenue segment.
Confidence: HIGH
What changedThe company has significantly expanded its footprint from 285 facilities at the end of FY25 to 304 by June 2026, while simultaneously improving PAT margins from 7.6% to 8.9% YoY.
Why it mattersThe results demonstrate the company's ability to scale rapidly (43% footprint increase in 18 months) without sacrificing profitability, maintaining a high OPM of 28.5% while capturing market share in the organized eye care segment.
Q1 FY27 Revenue: ₹614 CrPAT Growth (YoY): 44.6%Total Eye Care Facilities: 304EBITDA Margin: 28.5%Revenue vs TTM Revenue: ~29.5%
📅 Short termThe stock is likely to react positively to the strong double-digit growth in both revenue and PAT, alongside stable operating margins.
📈 Long termStructural growth is supported by the shift from unorganized to organized eye care and aggressive expansion into North and West India, though long-term success depends on the maturation of 78+ recently added centers.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risks related to the stabilization of 78 newly added centers
- Shortage of skilled ophthalmologists which could limit surgical capacity
Key Highlights
Revenue from operations increased 26.0% YoY to ₹614 Cr for the quarter ended June 30, 2026.
Added 18 new eye care facilities in Q1 FY27, reaching a total global footprint of 304 centers.
Profit After Tax (PAT) grew significantly by 44.6% YoY to ₹55 Cr compared to ₹38 Cr in Q1 FY26.
Mature facilities (operational >3 years) contributed 79% of total revenue, showing strong legacy performance.
Surgical procedures remain the dominant revenue driver, accounting for 65.9% of the total revenue mix.
👀 What to Watch
Investors should monitor the margin trajectory as the 18 newly added facilities ramp up, as emerging centers currently comprise 21% of revenue. Key focus should remain on the successful execution of the hub-and-spoke model in non-South Indian markets which now represent 31% of the network.
44.6% PAT Growth in Q1 FY27; 18 New Facilities Added and Nigeria Expansion Announced
Dr. Agarwal's Health Care reported a strong Q1 FY27 with revenue growing 26% YoY to ₹614 Cr and PAT increasing 44.6% to ₹55 Cr. The company achieved a record addition of 18 new facilities (16 surgical) in a single quarter, bringing its total network to 304 centers across 10 countries. EBITDA margins remained resilient at 28.5% despite the costs associated with 23 surgical facility launches in the last six months. Additionally, the board approved the incorporation of a new subsidiary in Nigeria to further its international footprint.
Confidence: HIGH
What changedThe company has significantly accelerated its expansion pace, adding nearly half of the previous year's total surgical facilities in just one quarter, while simultaneously initiating entry into the Nigerian market.
Why it mattersThe strong earnings growth combined with aggressive network expansion (now at 304 facilities) demonstrates high execution capability and the ability to scale the hub-and-spoke model without significant margin dilution.
Q1 Revenue from Operations: ₹614 CrQ1 Profit After Tax: ₹55 CrYoY Revenue Growth: 26.0%EBITDA Margin: 28.5%New Facilities Added (Q1): 18Total Network Count: 304
📅 Short termThe stock is likely to react positively to the strong bottom-line beat and the record number of facility additions, which signals robust future volume growth.
📈 Long termThe company is successfully transitioning from a regional player to a multi-national chain, with non-South Indian markets and international expansion providing a long-term growth runway.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Greenfield losses from rapid expansion of 23 surgical facilities in 6 months
- Regulatory and execution risks in the new Nigerian market
- Shortage of skilled ophthalmologists to staff new centers
Key Highlights
Revenue from operations grew 26.0% YoY to ₹614 Cr, driven by a 25.3% growth in the India business.
Profit After Tax (PAT) surged 44.6% YoY to ₹55 Cr, with PAT margins improving to 8.9% from 7.6%.
Added 18 new facilities in Q1 FY27, including a record 16 greenfield surgical facilities in a single quarter.
Total surgeries performed increased by 15.5% YoY to 91,082 procedures.
EBITDA grew 25.2% YoY to ₹177 Cr, maintaining a steady margin of 28.5%.
👀 What to Watch
Investors should monitor the gestation period and profitability ramp-up of the 18 newly added facilities, as greenfield expansions typically pressure margins initially. The successful entry into the Nigerian market will be a key milestone for the international segment's growth trajectory.
Unsecured Creditors Approve Amalgamation Scheme for Dr. Agarwal’s Health Care
Unsecured creditors of Dr. Agarwal’s Health Care Limited have approved the Scheme of Amalgamation with Dr. Agarwal’s Eye Hospital Limited in an NCLT-convened meeting held on July 02, 2026. This approval is a critical procedural step in the company's corporate restructuring process following the NCLT order dated May 05, 2026. The consolidation aims to streamline the group's operations, which currently include 258 centers and generated TTM revenue of Rs 2,080 Cr. The resolution was passed with the requisite majority as per the Scrutinizer's report.
Confidence: HIGH
What changedThe company has secured the necessary consent from its unsecured creditors for the proposed merger, moving the restructuring closer to completion.
Why it mattersConsolidating the hospital and healthcare entities simplifies the corporate structure, potentially improving operational efficiency and financial transparency for a company with a Rs 18,899 Cr market cap.
Meeting Date: July 02, 2026NCLT Order Date: May 05, 2026Current Centers: 258TTM Revenue: Rs 2,080 CrDebt to Equity: 0.34
📅 Short termThe news is likely to be viewed neutrally to slightly positively by the market as it indicates the restructuring is proceeding on schedule without creditor opposition.
📈 Long termThe merger will consolidate the group's 25% market share in the organized eye care segment and support its 20% expected growth rate by simplifying the management of its expanding network.
⚠ Risk flags
- Final NCLT approval pending
- Integration of entities post-merger
Key Highlights
Unsecured creditors approved the amalgamation scheme in a meeting held on July 02, 2026
The scheme involves the merger of Dr. Agarwal’s Eye Hospital Limited into Dr. Agarwal’s Health Care Limited
The meeting was conducted following an NCLT order issued on May 05, 2026
Company currently operates a network of 258 centers as of September 2025
TTM revenue stands at Rs 2,080 Cr with an operating profit margin of 28.5%
👀 What to Watch
Investors should monitor the next steps in the NCLT process, specifically the final hearing for the sanction of the scheme and the subsequent filing with the Registrar of Companies.
Secured Creditors Approve Amalgamation Scheme for Dr. Agarwal’s Health Care
Secured creditors of Dr. Agarwal’s Health Care Limited have approved the scheme of amalgamation with Dr. Agarwal’s Eye Hospital Limited in an NCLT-convened meeting held on July 02, 2026. This approval is a critical procedural milestone in the group's corporate restructuring process, following the NCLT order dated May 05, 2026. The company, which currently operates 258 centers and generates TTM revenue of Rs 2,080 Cr, aims to consolidate its operations. This consolidation is expected to streamline the corporate structure for a business with a 25% market share in the organized eye care segment.
Confidence: HIGH
What changedSecured creditors have formally consented to the merger of the two primary group entities, moving the restructuring closer to completion.
Why it mattersConsolidating the hospital and healthcare entities simplifies the corporate structure, potentially improving operational synergies and financial reporting for a company with a Rs 18,899 Cr market cap.
Meeting Date: July 02, 2026NCLT Order Date: May 05, 2026Total Centers: 258TTM Revenue: Rs 2080 CrDebt to Equity: 0.34
📅 Short termThe approval removes a significant regulatory hurdle, which is likely to be viewed positively by the market as it signals progress in corporate simplification.
📈 Long termStructural consolidation will likely streamline the management of the company's 25% market share in organized eye care and support its 20% expected growth rate.
⚠ Risk flags
- Integration risks post-merger
- Pending final NCLT sanction
Key Highlights
Meeting of secured creditors held on July 02, 2026, at 03:00 P.M. in Chennai.
Resolutions for the Scheme of Amalgamation approved by the requisite majority of secured creditors.
The company currently manages a network of 258 centers as of September 30, 2025.
Consolidation involves Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited.
The process follows an initial NCLT order dated May 05, 2026.
👀 What to Watch
Investors should monitor the next steps in the NCLT process, specifically the final sanction of the scheme and its subsequent filing with the Registrar of Companies (RoC).
Secured Creditors Approve Amalgamation for Rs 2,080 Cr Revenue Dr. Agarwal's Health Care
Secured creditors of Dr. Agarwal's Health Care Limited have approved the scheme of amalgamation with Dr. Agarwal’s Eye Hospital Limited in an NCLT-convened meeting held on July 02, 2026. This approval is a mandatory regulatory step toward consolidating the group's eye care business under a single entity. The company, which currently manages a debt of Rs 670 Cr and a network of 258 centers, is streamlining its corporate structure to improve operational efficiency. The resolution was passed by the requisite majority via remote e-voting and physical polling.
Confidence: HIGH
What changedSecured creditors have formally consented to the merger scheme, moving the corporate restructuring process to its next legal stage.
Why it mattersConsolidation of entities is expected to simplify the corporate structure and potentially lead to administrative cost savings for the Rs 18,899 Cr market cap company.
Meeting Date: July 02, 2026Total Debt: Rs 670 CrTTM Revenue: Rs 2,080 CrNetwork Size: 258 centers
📅 Short termPositive sentiment is expected as the merger process clears a significant regulatory milestone without creditor opposition.
📈 Long termThe merger will consolidate the company's estimated 25% market share in the organized eye care segment under a single corporate umbrella, potentially improving capital allocation.
⚠ Risk flags
- Final NCLT approval is still pending
- Integration risks post-merger
Key Highlights
Meeting of Secured Creditors held on July 02, 2026, following an NCLT order dated May 05, 2026.
The scheme involves the merger of Dr. Agarwal’s Eye Hospital Limited into Dr. Agarwal’s Health Care Limited.
Approval was granted by the requisite majority of secured creditors as per the Scrutinizer's Report.
The company currently operates 258 centers, representing a 43% increase in footprint since March 2024.
Consolidated TTM revenue stands at Rs 2,080 Cr with an operating profit margin of 28.5%.
👀 What to Watch
Monitor the timeline for the final NCLT sanction and the subsequent filing with the Registrar of Companies (RoC) to complete the merger process.
3 Secured Creditors: Dr. Agarwal's Health Care Holds Meeting for Amalgamation Scheme
Dr. Agarwal's Health Care Limited conducted an NCLT-convened meeting on July 02, 2026, to obtain secured creditor approval for the amalgamation of Dr. Agarwal's Eye Hospital Limited. The meeting involved 2 out of the 3 total secured creditors, satisfying the quorum requirement. This merger is a key step in the company's strategy to consolidate its organized eye care footprint, which currently includes 258 centers. The company maintains a debt of Rs 670 Cr against a market capitalization of Rs 18,899 Cr.
Confidence: HIGH
What changedThe company has successfully conducted the mandatory secured creditors' meeting, a critical regulatory step for its proposed merger.
Why it mattersThis consolidation is expected to simplify the corporate structure and potentially improve operational efficiency for the group, which holds a 25% market share in organized eye care.
Total Secured Creditors: 3Creditors Present: 2Debt: Rs 670 CrDebt to Market Cap: 3.54%Meeting Date: July 02, 2026
📅 Short termThe stock may remain neutral as this is a procedural update; market focus will shift to the final NCLT approval order.
📈 Long termStructural consolidation is generally positive for governance and operational efficiency in the organized eye care segment over the long term.
⚠ Risk flags
- Regulatory approval delays
- Integration of entities
Key Highlights
Meeting held on July 02, 2026, following the NCLT Chennai Bench order dated May 05, 2026
Total of 3 secured creditors were eligible to vote as of the record date, December 31, 2025
2 secured creditors attended the meeting, meeting the quorum requirement of 1 creditor
The resolution for amalgamation requires a Special Majority under Section 230(6) of the Companies Act, 2013
👀 What to Watch
Monitor the disclosure of the final voting results and the subsequent NCLT hearing for final sanction of the scheme.
99.97% Shareholder Approval for Amalgamation of Dr. Agarwal's Eye Hospital Entities
Shareholders of Dr. Agarwal's Health Care Limited have overwhelmingly approved the scheme of amalgamation with Dr. Agarwal's Eye Hospital Limited. In a court-convened meeting held on July 02, 2026, 99.97% of the 30.40 crore votes polled were in favor of the merger. The promoter group, holding 10.25 crore shares, voted 100% in favor, while public shareholders showed 99.96% support. This consolidation is a key step in streamlining the group's corporate structure as it manages its network of 258+ centers.
Confidence: HIGH
What changedShareholders have formally approved the merger of Dr. Agarwal's Eye Hospital Limited into Dr. Agarwal's Health Care Limited, moving the restructuring process toward final regulatory approval.
Why it mattersThis amalgamation simplifies the corporate structure of a major eye care player (25% organized market share), potentially leading to better operational synergies and administrative cost savings across its 258 centers.
Votes in favor (%): 99.97%Total votes polled: 30,40,15,565Public votes in favor (%): 99.96%Total shareholders: 43,122
📅 Short termThe overwhelming shareholder support removes a major hurdle, likely providing positive sentiment for the stock in the coming weeks as the merger progresses.
📈 Long termThe consolidation will likely streamline the balance sheet and operations, supporting the company's 20% growth target and its aggressive expansion into non-South Indian markets.
⚠ Risk flags
- Final approval from NCLT is still pending
- Integration risks associated with merging two large healthcare entities
Key Highlights
99.97% of total votes (30.39 crore shares) were cast in favor of the amalgamation scheme
100% of the 10.25 crore promoter group votes were cast in favor of the resolution
99.96% of public institutional and non-institutional votes supported the merger
Only 81,138 votes (0.03%) were cast against the resolution out of 30.40 crore total votes
The meeting was attended by 47 shareholders in person or via proxy out of a total base of 43,122
👀 What to Watch
Monitor the subsequent National Company Law Tribunal (NCLT) hearings for final sanction of the scheme and the announcement of the effective date for the merger.
Dr. Agarwal's Shareholders Meet to Approve Amalgamation with Eye Hospital Entity
Dr. Agarwal's Health Care Limited held an NCLT-convened meeting on July 02, 2026, to seek shareholder approval for the merger of Dr. Agarwal's Eye Hospital Limited into itself. The meeting was attended by 47 shareholders, meeting the NCLT-prescribed quorum of 30. This amalgamation is a significant restructuring step for the group, which currently operates 258 centers and generates TTM revenue of 2,080 Cr. Voting results from remote e-voting and the venue poll are being consolidated by the scrutinizer.
Confidence: HIGH
What changedThe company has successfully conducted the court-convened shareholder meeting, a critical procedural milestone in the legal process of merging its group entities.
Why it mattersThe merger simplifies the corporate structure by consolidating eye care operations under one entity, potentially improving operational efficiency and financial reporting for a business with a 25% market share in organized eye care.
Record Date: June 03, 2026Total Shareholders: 43,122Quorum Required: 30Shareholders Present: 47Current Centers: 258
📅 Short termThe completion of the meeting is a positive procedural step; the stock may react neutrally to mildly positive as the merger moves closer to finalization.
📈 Long termThe amalgamation is structurally significant, likely leading to better synergy and a cleaner balance sheet for the group's long-term expansion strategy.
⚠ Risk flags
- Regulatory approval risk from NCLT
- Integration risk of merging entities
Key Highlights
Meeting held on July 02, 2026, to approve the Scheme of Amalgamation between the company and Dr. Agarwal's Eye Hospital Limited.
Total shareholder base stood at 43,122 as of the record date of June 03, 2026.
A total of 47 shareholders (17 Promoters and 30 Public) attended the meeting, surpassing the required quorum of 30.
The company currently manages 258 centers, having added 78 centers since March 2024.
The resolution requires a Special Majority as prescribed under Section 230(6) of the Companies Act, 2013.
👀 What to Watch
Investors should monitor the upcoming disclosure of the consolidated voting results and the subsequent final approval from the NCLT Chennai Bench to confirm the merger timeline.
Dr. Agarwal's Health Care Schedules July 2 Meeting for Amalgamation Approval
Dr. Agarwal's Health Care Limited has scheduled NCLT-convened meetings for its equity shareholders and unsecured creditors on July 02, 2026, in Chennai. The meetings are intended to seek approval for the proposed Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited. Shareholders as of the cut-off date of June 03, 2026, are eligible to participate in remote e-voting from June 07 to July 01, 2026. This consolidation is a key step in the group's corporate restructuring process.
Key Highlights
NCLT-convened meeting for Equity Shareholders scheduled for July 02, 2026, at 12:30 P.M.
Unsecured Creditors meeting scheduled for the same day, July 02, 2026, at 04:00 P.M.
Remote e-voting period begins on June 07, 2026, and ends on July 01, 2026.
Cut-off date for determining shareholder eligibility for e-voting is June 03, 2026.
The meeting aims to approve the Scheme of Amalgamation between the company and Dr. Agarwal’s Eye Hospital Limited.
👀 What to Watch
Investors should review the merger terms in the provided notice and exercise their voting rights during the e-voting window. Monitor the progress of the NCLT approval process as this consolidation may lead to operational synergies.
Dr. Agarwal's Health Care to Convene Creditor Meeting for Merger with Dr. Agarwal's Eye Hospital
Dr. Agarwal's Health Care Limited (AHCL) has scheduled a meeting for its secured creditors on July 02, 2026, to approve the Scheme of Amalgamation with Dr. Agarwal's Eye Hospital Limited (AEHL). This follows the NCLT Chennai Bench's order dated May 05, 2026, and previous no-objection letters from NSE and BSE in February 2026. The merger aims to consolidate the hospital and healthcare operations under a single entity to improve operational efficiencies. Shareholders and creditors will vote on the resolution, with remote e-voting starting June 07, 2026.
Key Highlights
NCLT-convened meeting for secured creditors scheduled for July 02, 2026, in Chennai.
Remote e-voting period for eligible creditors is set from June 07, 2026, to July 01, 2026.
Valuation and fairness opinions were finalized on August 26, 2025, by PwC and Kotak Mahindra Capital.
NSE and BSE issued no-objection letters for the scheme on February 16 and 17, 2026, respectively.
The merger involves the consolidation of AEHL (Transferor) into AHCL (Transferee) under Sections 230-232 of the Companies Act.
👀 What to Watch
Investors should monitor the outcome of the July 02 meeting as the successful amalgamation will streamline the corporate structure and potentially enhance shareholder value through synergies. No immediate action is required until the final NCLT approval is received post-creditor voting.
Dr. Agarwal's Health Care Schedules July 2 Creditors Meeting for AEHL Amalgamation
Dr. Agarwal's Health Care Limited (AHCL) is proceeding with its merger with Dr. Agarwal's Eye Hospital Limited (AEHL) by convening a meeting of secured creditors on July 2, 2026. This follows an order from the NCLT Chennai Bench dated May 5, 2026, as part of the formal approval process for the Scheme of Amalgamation. Remote e-voting for eligible creditors will be open from June 7 to July 1, 2026. The merger is supported by valuation reports and fairness opinions from major firms including PwC, Kotak Mahindra Capital, and Motilal Oswal.
Key Highlights
NCLT-convened meeting of secured creditors scheduled for July 2, 2026, at 3:00 PM IST in Chennai.
Remote e-voting period for creditors set from June 7, 2026, to July 1, 2026.
The merger involves the consolidation of Dr. Agarwal’s Eye Hospital Limited (AEHL) into Dr. Agarwal’s Health Care Limited (AHCL).
Fairness opinions for the deal were issued on August 26, 2025, by Kotak Mahindra Capital and Motilal Oswal Investment Advisors.
The cut-off date for determining eligible voting creditors was fixed as December 31, 2025.
👀 What to Watch
Investors should monitor the outcome of the creditors' meeting on July 2, as their approval is a vital regulatory milestone for the completion of the group's consolidation.
Dr. Agarwal's Health Care Sets July 2 Meeting for Merger with Dr. Agarwal’s Eye Hospital
Dr. Agarwal's Health Care Limited (AHCL) has scheduled an NCLT-convened meeting on July 2, 2026, to seek shareholder approval for its merger with Dr. Agarwal’s Eye Hospital Limited (AEHL). The company has established June 3, 2026, as the cut-off date for voting eligibility, with remote e-voting available from June 7 to July 1, 2026. This consolidation is supported by valuation reports from PwC and Bansi S. Mehta, and fairness opinions from Kotak Mahindra and Motilal Oswal. The merger aims to streamline the group's corporate structure and eye care operations.
Key Highlights
Shareholder meeting scheduled for July 2, 2026, at 12:30 P.M. in Chennai per NCLT directions.
Remote e-voting period starts June 7, 2026, and concludes on July 1, 2026.
Cut-off date for determining voting eligibility for equity shareholders is June 3, 2026.
Merger involves the amalgamation of Dr. Agarwal’s Eye Hospital Limited (AEHL) into Dr. Agarwal’s Health Care Limited (AHCL).
Valuation and fairness opinions were issued on August 26, 2025, by leading firms including PwC and Kotak Mahindra Capital.
👀 What to Watch
Shareholders should review the merger's share exchange ratio and fairness opinions to understand the valuation impact. Voting in favor is generally advisable for long-term consolidation benefits and operational synergies.
Dr. Agarwal's FY26 Revenue Crosses ₹2,000 Cr; PAT Surges 52.4% YoY
Dr. Agarwal's Health Care Limited achieved a significant milestone in FY26, with total income crossing ₹2,000 crores to reach ₹2,125 crores, a 20.9% YoY increase. Profit After Tax (PAT) grew substantially by 52.4% to ₹168 crores, supported by a 25% increase in patient walk-ins and a network expansion to 269 facilities. The company demonstrated strong operational leverage with EBITDA margins improving to 28.9%. Management has provided aggressive guidance for FY27, planning to commission 60 new facilities to further penetrate the North and West Indian markets.
Key Highlights
Annual revenue from operations rose 21.6% YoY to ₹2,080 crores, crossing the ₹2,000 Cr milestone for the first time.
Full-year PAT surged 52.4% to ₹168 crores with PAT margins expanding by 164 basis points to 7.9%.
Network expanded to 269 facilities across 155 cities, including 19 new greenfield facilities launched in Q4 alone.
High-end robotic cataract surgeries (Femto) grew by 87% YoY, indicating a successful shift toward premium clinical procedures.
Management plans to add 60 new facilities in FY27, with a specific focus on doubling additions in the North and West regions.
👀 What to Watch
Investors should monitor the execution of the aggressive 60-center expansion plan in FY27, which could drive further scale and margin expansion. The strong growth in high-end surgical procedures and successful entry into Delhi NCR are positive indicators of long-term value creation.
Dr. Agarwal's Health Care Invests USD 200,000 in Ethiopian Subsidiary
Dr. Agarwal's Health Care Limited has finalized an investment of USD 200,000 in its newly incorporated entity, Orbit Health Care ETH PLC, located in Ethiopia. The investment was channeled through its wholly-owned subsidiary, Orbit Healthcare Services (Mauritius) Limited. As a result, the Ethiopian unit is now a step-down wholly-owned subsidiary of the company. This move marks a strategic step in the company's international expansion efforts within the African region.
Key Highlights
Completed investment of USD 200,000 for share subscription in Orbit Health Care ETH PLC
Orbit Health Care ETH PLC becomes a step-down wholly-owned subsidiary of the company
Investment executed via Mauritius-based subsidiary Orbit Healthcare Services
Strategic entry into the Ethiopian healthcare market to drive international growth
👀 What to Watch
Investors should view this as a positive step towards geographical diversification, though the initial investment is relatively small. Monitor future capital allocations to this region to gauge the scale of international operations.
Dr. Agarwal's Health Care FY26 PAT Surges 52.4% to ₹168 Cr; Total Income Hits ₹2,125 Cr
Dr. Agarwal's Health Care reported a strong financial performance for FY26, with total income growing 20.9% YoY to ₹2,125 crore. Profit After Tax (PAT) saw a significant jump of 52.4%, reaching ₹168 crore, driven by operational efficiencies and network expansion. The company added 57 new facilities during the year, bringing the total to 288 across India and international markets. With a robust Same Store Sales Growth (SSSG) of 14.1% and plans to add another 60 facilities in FY27, the company demonstrates aggressive growth momentum.
Key Highlights
Total Income grew 20.9% YoY to ₹2,125 Cr in FY26, while EBITDA rose 22.2% to ₹614 Cr.
Net Profit (PAT) increased by 52.4% YoY to ₹168 Cr, with PAT margins improving from 6.3% to 7.9%.
Network expanded significantly with 57 new facility additions in FY26, reaching a total of 288 facilities across 10 countries.
Achieved a healthy Same Store Sales Growth (SSSG) of 14.1% for facilities operational up to FY23.
Aggressive expansion guidance provided for FY27 with a target of 60 new facilities (30 per half-year).
👀 What to Watch
Investors should focus on the company's ability to maintain high SSSG while scaling its network rapidly. The significant margin improvement and the maturing of 'Emerging Facilities' (currently 21.3% of revenue) present a strong case for long-term value creation.
Dr. Agarwal's Health Care FY26 PAT Jumps 52% to ₹168 Cr; Revenue Crosses ₹2,000 Cr Milestone
Dr. Agarwal's Health Care reported a stellar performance for FY2026, with total income crossing the ₹2,000 crore milestone to reach ₹2,125 crores, a 20.9% YoY growth. Net profit surged by 52.4% YoY to ₹168 crores, driven by aggressive network expansion and a 14.5% increase in total surgeries. The company added 57 new centers during the year, bringing its total network to 288 facilities across 10 countries. Furthermore, the board has reallocated ₹14.88 crores of unspent IPO issue expenses toward unidentified inorganic acquisitions and general corporate purposes to support future growth.
Key Highlights
FY26 Total Income grew 20.9% YoY to ₹2,125 Crores, marking a significant scale milestone.
Full-year Profit After Tax (PAT) increased by 52.4% YoY to ₹168 Crores with PAT margins improving from 6.3% to 7.9%.
Aggressive expansion with 57 new facilities added in FY26 (one per week), reaching a total of 288 centers.
EBITDA for the year rose 22.2% to ₹614 Crores, maintaining healthy margins at 28.9%.
Board approved reallocating ₹14.88 Cr of unspent IPO proceeds to support future inorganic acquisitions.
👀 What to Watch
Investors should view the strong revenue growth and margin expansion as a sign of successful scaling and operational leverage. Monitor the company's upcoming inorganic acquisitions as they utilize the reallocated IPO funds to further consolidate the eye care market.
Dr. Agarwal's Health Care Receives ₹20.50 Crore GST Show Cause Notice
Dr. Agarwal's Health Care Limited has received a Show Cause Notice (SCN) from the GST authorities in Chennai for the financial year 2023-24. The notice alleges various discrepancies including excess Input Tax Credit (ITC) claims, short payment of tax under RCM, and e-invoicing non-compliance. The total demand, which includes tax, interest, and penalties, amounts to ₹20.50 Crores. The company has 30 days to respond and currently maintains that this will not have a significant impact on its operations or financials.
Key Highlights
Total GST demand of ₹20.50 Crores including interest and penalties for FY 2023-24
Allegations involve differences in output turnover, excess ITC claims, and RCM short payments
The company is required to show cause before the Assistant Commissioner within 30 days
Management currently expects no material impact on the company's financial or operational activities
👀 What to Watch
Investors should monitor the outcome of the company's response to the tax authorities, as a final adverse order would result in a cash outflow of ₹20.50 Crores. No immediate action is necessary while the matter is at the show-cause stage.
Dr. Agarwal's Health Care Receives ₹15.08 Cr GST Show Cause Notice for FY 2022-23
Dr. Agarwal's Health Care Limited has received a Show Cause Notice (SCN) from the GST authorities in Chennai alleging discrepancies for the financial year 2022-23. The notice demands a GST payment of ₹15.08 Crores, along with applicable interest and penalties, citing issues like short payment under RCM and excess Input Tax Credit claims. The company has been given 30 days to respond to the allegations. Management currently maintains that they do not expect a significant impact on the company's financials or operations.
Key Highlights
GST demand of ₹15.08 Crores plus interest and penalties for FY 2022-23
Allegations include discrepancies in output turnover, RCM short payments, and ineligible ITC claims
Notice issued by the Office of the Assistant Commissioner, GST & Central Excise, Chennai
Company has 30 days to file a formal reply contesting the demand
👀 What to Watch
Investors should monitor the outcome of the company's reply to the GST department to see if the demand is reduced or waived. While the amount is notable, it is currently at the show-cause stage and not a final confirmed liability.
Dr. Agarwal's Health Care Board Meeting on May 21, 2026, to Approve Q4 and FY26 Results
Dr. Agarwal's Health Care Limited has scheduled a Board Meeting on May 21, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. Following the board meeting, the company will host an earnings conference call at 6:30 P.M. IST to discuss the annual performance. Key management personnel, including the CEO and CFO, will be present to address investor queries. The trading window for insiders remains closed until 48 hours after the results are declared.
Key Highlights
Board meeting scheduled for May 21, 2026, to approve Q4 and FY26 audited financial results.
Earnings conference call set for 06:30 P.M. IST on May 21, 2026, for analyst interaction.
CEO Dr. Adil Agarwal and CFO Yashwanth Venkat will represent the company on the call.
Trading window closed for insiders until 48 hours post-announcement of results.
The meeting will cover both standalone and consolidated financial performance for the full year.
👀 What to Watch
Investors should monitor the results on May 21 for margin trends and expansion updates, and participate in the conference call to understand the management's outlook for FY27.
